Skip to main content

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Report on 2022 Annual Meeting of Stockholders Voting, Partial Adjournment

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, is reporting on business conducted during its 2022 Annual Meeting of Stockholders. According to the announcement, the meeting was partially adjourned and will reconvene on Oct. 28, 2022, to vote on proposals no. 5 and no. 6. That decision, stated the company, was made to “provide the company with additional time to solicit and collect proxies in favor of proposal nos. 5 and 6. Proposal nos. 5 and 6 have not yet received sufficient votes for approval, therefore, the Annual Meeting will be reconvened. . . solely with respect to proposal Nos. 5 and 6.” Board members did vote on four of the six proposals on the meeting agenda, including electing director nominees, approving compensation paid to the company’s executive officers, advising that the company hold a Say-on-Pay vote every year and ratifying the appointment of WithumSmith+Brown, PC, as the company’s independent registered public accounting firm. Proposal no. 5 grants discretionary authority to the company to implement a reverse stock split of issued and outstanding shares of common stock if necessary to, among other things, maintain the company’s listing on the NASDAQ Capital Market. Proposal no. 6 will approve an amendment allowing the board to determine the number of directors making up the board of directors. The deadline for stockholders to vote is 8:59 p.m. PT on Oct. 27, 2022.

To view the full press release, visit

About VistaGen Therapeutics Inc.

VistaGen is a late clinical-stage biopharmaceutical aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than those that are currently available. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless and tasteless investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. VistaGen is passionate about transforming mental-health care and redefining what is possible in the treatment of anxiety and depression. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.